Product Details
Emoclot 500iu/10ml Human Plasma Coagulation Factor VIII Infusion In Pakistan
Emoclot 500 IU/10ml Human Plasma Coagulation Factor VIII is a plasma-derived coagulation factor medicine containing human coagulation Factor VIII. It is used as replacement therapy when Factor VIII activity is deficient, particularly for the treatment and prevention of bleeding associated with Haemophilia A. It may also be used in selected cases of acquired Factor VIII deficiency and under specialist supervision when Factor VIII inhibitors are present.
Emoclot 500 IU is supplied as a lyophilised powder together with a 10 mL solvent for reconstitution. After reconstitution, the preparation contains approximately 500 IU of Factor VIII in 10 mL, equivalent to about 50 IU/mL. The product is manufactured from plasma obtained from human donors and also contains human von Willebrand factor.
Benefits
- Provides replacement of deficient human coagulation Factor VIII.
- Used for treatment of bleeding episodes associated with Factor VIII deficiency.
- Can be used for prevention of bleeding in appropriately diagnosed patients with Haemophilia A.
- Helps temporarily restore Factor VIII activity and support normal blood coagulation.
- May be used in selected cases of acquired Factor VIII deficiency.
- Supplied in a defined 500 IU/10 mL presentation for professional medical use.
Specifications
| Specification | Details |
|---|---|
| Product Name | Emoclot 500 IU/10 mL |
| Active Ingredient | Human Plasma Coagulation Factor VIII |
| Strength | 500 IU per vial |
| Reconstituted Concentration | Approximately 50 IU/mL |
| Total Volume | 10 mL |
| Pharmaceutical Form | Powder and solvent for solution for infusion |
| Source | Human donor plasma |
| Specific Activity | Approximately 80 IU/mg protein |
| Additional Protein | Human von Willebrand Factor |
| Administration | Intravenous |
| Manufacturer | Kedrion S.p.A., Italy |
| Storage | Generally 2°C–8°C; do not freeze |
The exact storage and handling requirements should always be checked against the product's current package insert and labelled instructions.
How To Use
Emoclot should only be prepared and administered by appropriately trained healthcare professionals. It is administered intravenously after reconstitution with the supplied solvent.
The required dose and frequency are individualized according to the patient's Factor VIII level, body weight, severity and location of bleeding, clinical response, and whether treatment is being given for bleeding control or prevention. Therefore, a fixed dose should not be recommended for self-treatment.
Before administration, the reconstituted solution should be visually inspected. Product information indicates that the solution should be clear or slightly opalescent; a cloudy solution or one containing abnormal deposits should not be used.
Patients receiving Factor VIII replacement can develop Factor VIII inhibitors, which may reduce treatment effectiveness. Hypersensitivity reactions can also occur, so appropriate medical supervision is important.
Why Choose Emoclot 500 IU/10 mL?
Emoclot provides human plasma-derived Factor VIII in a standardized 500 IU presentation. Its established formulation is designed for replacement therapy in patients with Factor VIII deficiency and is supplied with the solvent required for reconstitution.
The 500 IU/10 mL presentation provides approximately 50 IU/mL after reconstitution, allowing healthcare professionals to administer treatment according to the patient's individually calculated clinical requirement.
